Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of JR-141 in Mucopolysaccharidosis II
NCT03708965Phase 2Active, not recruiting
- Sponsor
- JCR Pharmaceuticals
- Start
- Jan 2019
- Primary completion
- Dec 2026
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of pabinafusp alfa in mucopolysaccharidosis type 2, sponsored by JCR Pharmaceuticals. Started Jan 2019; status: active, not recruiting.
02
Drugs
pabinafusp alfa
03
Conditions
mucopolysaccharidosis type 2
Beyond the preview
Go deeper on NCT03708965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03708965.